News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
437,188 Results
Type
Article (31105)
Company Profile (116)
Press Release (405963)
Multimedia
Podcasts (73)
Webinars (12)
Section
Business (106159)
Career Advice (548)
Deals (18690)
Drug Delivery (97)
Drug Development (51922)
Employer Resources (81)
FDA (11743)
Job Trends (10409)
News (193327)
Policy (22290)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Standard (3)
Academia (2161)
Academic (2)
Accelerated approval (29)
Adcomms (27)
Allergies (106)
Alliances (29378)
ALS (117)
Alzheimer's disease (1276)
Antibody-drug conjugate (ADC) (187)
Approvals (12012)
Artificial intelligence (372)
Autoimmune disease (92)
Automation (20)
Bankruptcy (158)
Best Places to Work (9278)
BIOSECURE Act (8)
Biosimilars (164)
Biotechnology (58)
Bladder cancer (126)
Brain cancer (38)
Breast cancer (429)
Cancer (3048)
Cardiovascular disease (343)
Career advice (512)
Career pathing (15)
CAR-T (134)
CDC (51)
Celiac Disease (1)
Cell therapy (411)
Cervical cancer (29)
Clinical research (46675)
Collaboration (1082)
Company closure (1)
Compensation (164)
Complete response letters (37)
COVID-19 (2415)
CRISPR (57)
C-suite (502)
Cystic fibrosis (101)
Data (4433)
Decentralized trials (2)
Denatured (22)
Depression (127)
Diabetes (380)
Diagnostics (5200)
Digital health (45)
Diversity (10)
Diversity, equity & inclusion (24)
Drug discovery (145)
Drug pricing (177)
Drug shortages (12)
Duchenne muscular dystrophy (158)
Earnings (39061)
Editorial (46)
Employer branding (8)
Employer resources (73)
Events (78683)
Executive appointments (666)
FDA (14136)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (4)
Frontotemporal dementia (20)
Funding (1064)
Gene editing (108)
Generative AI (35)
Gene therapy (345)
GLP-1 (687)
Government (4560)
Grass and pollen (6)
Guidances (297)
Healthcare (15385)
HIV (52)
Huntington's disease (33)
IgA nephropathy (74)
Immunology and inflammation (147)
Immuno-oncology (34)
Indications (75)
Infectious disease (2664)
Inflammatory bowel disease (137)
Inflation Reduction Act (16)
Influenza (110)
Intellectual property (119)
Interviews (60)
IPO (8157)
IRA (43)
Job creations (1519)
Job search strategy (451)
JPM (60)
Kidney cancer (11)
Labor market (41)
Layoffs (290)
Leadership (11)
Legal (4028)
Liver cancer (72)
Longevity (12)
Lung cancer (432)
Lymphoma (229)
Machine learning (21)
Management (30)
Manufacturing (415)
MASH (139)
Medical device (9879)
Medtech (9923)
Mergers & acquisitions (11214)
Metabolic disorders (955)
Multiple sclerosis (130)
NASH (20)
Neurodegenerative disease (235)
Neuropsychiatric disorders (77)
Neuroscience (2224)
Neurotech (1)
NextGen: Class of 2026 (5092)
Non-profit (3972)
Now hiring (13)
Obesity (424)
Opinion (178)
Ovarian cancer (96)
Pain (133)
Pancreatic cancer (125)
Parkinson's disease (205)
Partnered (21)
Patents (232)
Patient recruitment (357)
Peanut (40)
People (34123)
Pharmaceutical (32)
Pharmacy benefit managers (29)
Phase 1 (12436)
Phase 2 (19523)
Phase 3 (17938)
Pipeline (3734)
Policy (250)
Postmarket research (1782)
Preclinical (3681)
Press Release (49)
Prostate cancer (162)
Psychedelics (40)
Radiopharmaceuticals (172)
Rare diseases (624)
Real estate (2920)
Recruiting (33)
Regulatory (17127)
Reports (27)
Research institute (1999)
Resumes & cover letters (40)
Rett syndrome (21)
RNA editing (6)
RSV (70)
Schizophrenia (134)
Series A (169)
Series B (135)
Service/supplier (4)
Sickle cell disease (77)
Special edition (13)
Spinal muscular atrophy (116)
Sponsored (30)
Startups (2157)
Stomach cancer (8)
Supply chain (71)
Tariffs (52)
The Weekly (50)
Vaccines (882)
Venture capital (67)
Weight loss (261)
Women's health (84)
Worklife (7)
Date
Today (11)
Last 7 days (374)
Last 30 days (1547)
Last 365 days (20459)
2026 (2015)
2025 (20837)
2024 (23571)
2023 (26327)
2022 (35790)
2021 (39255)
2020 (39395)
2019 (34737)
2018 (26059)
2017 (19358)
2016 (20014)
2015 (22890)
2014 (16964)
2013 (13268)
2012 (14045)
2011 (14494)
2010 (12571)
Location
Africa (543)
Alabama (65)
Alaska (6)
Arizona (185)
Arkansas (11)
Asia (24229)
Australia (4343)
California (6931)
Canada (2235)
China (694)
Colorado (327)
Connecticut (347)
Delaware (225)
Europe (54374)
Florida (1052)
Georgia (295)
Hawaii (2)
Idaho (39)
Illinois (624)
India (55)
Indiana (477)
Iowa (13)
Japan (335)
Kansas (93)
Kentucky (27)
Louisiana (24)
Maine (79)
Maryland (1001)
Massachusetts (5014)
Michigan (224)
Minnesota (410)
Mississippi (3)
Missouri (119)
Montana (19)
Nebraska (21)
Nevada (95)
New Hampshire (63)
New Jersey (2350)
New Mexico (12)
New York (2105)
North Carolina (1018)
North Dakota (4)
Northern California (3433)
Ohio (227)
Oklahoma (13)
Oregon (28)
Pennsylvania (1525)
Puerto Rico (12)
Rhode Island (29)
South America (691)
South Carolina (34)
South Dakota (1)
Southern California (2638)
Tennessee (139)
Texas (1048)
United States (26588)
Utah (276)
Virginia (159)
Washington D.C. (56)
Washington State (651)
West Virginia (3)
Wisconsin (89)
Wyoming (2)
437,188 Results for "endpoint health".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Brain cancer
Imvax Heads to FDA With 6-Month Survival Gain in Glioblastoma, Despite Endpoint Miss
While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, the company will request a meeting with the FDA to discuss next steps for “synergistic” treatment.
December 2, 2025
·
2 min read
·
Dan Samorodnitsky
Regulatory
FDA’s Tidmarsh Singles Out Aurinia’s Drug in LinkedIn Post About Surrogate Endpoints
Without naming Aurinia Pharmaceuticals, the CDER director in a now-deleted LinkedIn post claimed that for lupus nephritis, companies have not conducted post-approval studies “to demonstrate a benefit on hard clinical endpoints.”
September 30, 2025
·
2 min read
·
Tristan Manalac
Lymphoma
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result “doesn’t waver our optimism” regarding the bispecific antibody’s ongoing frontline trial.
January 19, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Australia’s Department of Health has issued import permits for Optimi’s MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme
January 26, 2026
·
1 min read
Press Releases
As mental health patients turn to AI chatbots, how can pharma lead the way?
A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.
February 5, 2026
·
1 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
·
11 min read
Press Releases
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
January 9, 2026
·
6 min read
Press Releases
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
December 16, 2025
·
3 min read
Press Releases
Privo Technologies Announces Milestone in PRV211 Arm of CLN-004 Clinical Trial: Primary Endpoint Met; No Serious Adverse Events Reported
January 26, 2026
·
3 min read
Press Releases
RSNA25: Pediatric Study for Bayer’s Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
December 4, 2025
·
6 min read
1 of 43,719
Next
